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Background
CAVATAK, an oncolytic immunotherapy, is a bio-
selected oncolytic strain of Coxsackievirus A21 (CVA21).
Following intratumoral (IT) injection, CVA21 preferen-
tially infects ICAM-1 expressing tumor cells, resulting in
viral replication, cell lysis, and a systemic anti-tumor
immune response. The Phase II CALM study investigated
the efficacy and safety of IT CVA21 in pts with advanced
melanoma. The primary endpoint of the study was
achieved with 22 of 57 (38.6%) evaluable pts with durable
responses observed in both injected and uninjected mela-
noma metastases, suggesting the generation of significant
host anti-tumor responses. Pre-clinical studies in an
immune-competent mouse model of melanoma revealed
that combinations of intratumoral CAVATAK and anti-
PD-1 or anti-CTLA-4 mAbs mediated significantly
greater anti-tumor activity compared to use of either
agent alone. Here we report on a continuation study
aimed at understanding the immune mediated effects of
CVA21.
Methods
To further elucidate the nature of the systemic anti-
tumor responses, a CALM study (NCT01227551) exten-
sion cohort of 13 pts received up to 3 x 108 TCID50
CVA21 IT on study days 1,3,5 and 8 and then every
three weeks for a further 6 injections. Sequential tumor
biopsies of both injected and uninjected lesions were
monitored for levels of viral replication and evidence of
viral-induced immune activation within the tumor
micro-environment. Serial serum samples were moni-
tored for viral loads, anti-CVA21 neutralizing antibody
(nAb) and levels of immune-inflammatory cytokines.
Results
CVA21 administration was shown in 5 of 6 cases to
induce increases in immune cell infiltrates within the
tumor microenvironment, in particular CD8+cells and
increased expression of PD-L1+ cells as assessed by mul-
tispectral imaging. Reconstitution of immune cell infil-
trates was observed in 4 of 4 of CVA21 treated lesions
from patients failing treatment with single or double-
line immune-checkpoint blockade. Analysis of 4 pre-
and post-treatment biopsy samples by NanoString digital
RNA counting identified sizable up-regulation of a num-
ber of immune modulation elements, including a Th1-
gene shift, with increases in interferon-induced genes.
Conclusions
Intralesional administration of CVA21 can notably influ-
ence the dynamics of the tumor micro-environment as
evidenced by increases in immune cell infiltrates and
immune-related response genes. Our observation that
CVA21 can reconstitute immune cell infiltrates in
lesions resistant to immune-checkpoint blockade pro-
vides a strong rationale for the investigation of the
sequential or concurrent administration of CVA21 and
T cell checkpoint antibodies. A clinical trial combining
CVA21 with anti-CTLA-4 is underway and other com-
bination studies are planned.8Viralytics, Sydney, Australia
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